GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » Valuation Rank

Bionano Genomics (MEX:BNGO) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Bionano Genomics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bionano Genomics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » Valuation Rank
Comparable Companies
EKSO MHUA LUCY CBSC POAI NEPH YBGJ IMTH ECIA RSCF ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XSWX:STMN XPAR:DIM
Traded in Other Exchanges
BNGO:USA 0A4K:UK
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Website
https://www.bionano.com
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.